NCT01378546

Treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) With 3, 4 DAP

Treatment of Lambert-Eaton Myasthenic Syndrome and Congenital Myasthenic Syndromes With 3, 4-Diaminopyridine

• Status: No Longer Available
• Phase: —
• Study type: Expanded Access
• Enrollment: —
• Sponsor: Louis H. Weimer, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Lambert Eaton Myasthenic Syndrome (LEMS) is rare neurological disorder that results in muscle weakness and limited reflex activity. More than half of LEMS cases are associated with a malignancy, usually small cell lung cancer, and tend to progress more quickly than cases not coupled with malignant cells. 3,4diaminopyridine (3,4DAP)is a drug that has been demonstrated to be effective in treating the weakness associated with LEMS as it increases strength and improves autonomic symptoms in LEMS patients. It is not currently approved by the FDA for use in the United States. The investigators plan to use 3,4DAP to treat patients with LEMS here at the Columbia University MDA/ALS Research Center.

Conditions

• Lambert Eaton Myasthenic Syndrome (LEMS)

Interventions

Type	Name	Description
DRUG	3,4-diaminopyridine	Treatment will begin with 5mg three times a day or less.

Timeline

• Start date: 2005-05-01
• Primary completion: 2015-05-01
• First posted: 2011-06-22
• Last updated: 2013-07-18

Locations

1 site across 1 country: United States